Johnson & Johnson received U.S. Food and Drug Administration approval for its TECNIS PureSee intra‑ocular lens (IOL) on March 12 2026. The lens is an extended‑depth‑of‑focus (EDOF) device that uses a purely refractive, non‑diffractive optical design to extend clear vision beyond the near range without the visual disturbances that can accompany other premium lenses.
The approval marks the first time a U.S. FDA‑approved EDOF IOL has been cleared without a warning about loss of contrast sensitivity, a key differentiator for surgeons and patients. Clinical data show that 97 % of patients reported no very bothersome visual disturbances such as halos or glare, and 97 % would recommend the lens to friends or family, underscoring the high level of patient satisfaction.
The TECNIS PureSee will become available to U.S. patients later in 2026 and joins Johnson & Johnson’s existing TECNIS portfolio, which includes the TECNIS Odyssey and TECNIS Eyhance lenses. The new product expands the company’s ophthalmology lineup and provides a new option for cataract surgeons seeking spectacle‑independent outcomes.
The extended‑depth‑of‑focus market is projected to reach $2,114 million by 2025 with a 16.8 % compound annual growth rate, driven by an aging population and increasing demand for premium intra‑ocular lenses. Competitors such as Alcon’s AcrySof IQ Vivity and Zeiss offer EDOF solutions, but the PureSee’s lack of a contrast‑sensitivity warning positions it as a compelling alternative in a crowded field.
Johnson & Johnson’s MedTech segment, which includes the Vision business, reported operational sales growth of 5.4 % in full‑year 2025, led by strong performance in electrophysiology, Abiomed, and wound‑closure products. The Vision segment’s expansion with the PureSee lens is expected to contribute to the company’s target of 5‑7 % MedTech growth through 2027, reinforcing its strategy to capture a larger share of the premium eye‑care market.
Peter Menziuso, Company Group Chairman for Vision, said, “Today marks an exciting milestone for people living with cataracts. The approval of the TECNIS PureSee IOL gives surgeons an important new lens option, reflecting our deep commitment to innovation that delivers high patient satisfaction and supports vision solutions tailored to individual lifestyle needs.” He added that the lens will help patients regain not just sight, but the quality, range, and visual performance they expect from a Johnson & Johnson product.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.